CNS Pharmaceuticals Inc. [CNSP] Is Currently -0.75 below its 200 Period Moving Avg: What Does This Mean?


CNS Pharmaceuticals Inc. [NASDAQ: CNSP] price plunged by -0.75 percent to reach at $0.0. The company report on June 23, 2022 that CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Expanded eligibility for patients who have received multiple therapies as first line therapy for GBM.

Company continues to enroll patients for the trial with 19 clinical trial sites open to-date, and an additional 42 sites selected across the U.S., Italy, France, Spain, and Switzerland that will be initiated and enrolling soon.

A sum of 11574613 shares traded at recent session while its average daily volume was at 705.74K shares. CNS Pharmaceuticals Inc. shares reached a high of $0.3768 and dropped to a low of $0.2675 until finishing in the latest session at $0.28.

The one-year CNSP stock forecast points to a potential upside of 95.33. The average equity rating for CNSP stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on CNS Pharmaceuticals Inc. [CNSP]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CNSP shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CNSP stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Ladenburg Thalmann have made an estimate for CNS Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 28, 2020. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on August 24, 2020, representing the official price target for CNS Pharmaceuticals Inc. stock.

The Average True Range (ATR) for CNS Pharmaceuticals Inc. is set at 0.03 The Price to Book ratio for the last quarter was 0.73, with the Price to Cash per share for the same quarter was set at 0.32.

CNSP Stock Performance Analysis:

CNS Pharmaceuticals Inc. [CNSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.91. With this latest performance, CNSP shares dropped by -2.87% in over the last four-week period, additionally sinking by -69.53% over the last 6 months – not to mention a drop of -86.10% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CNSP stock in for the last two-week period is set at 43.46, with the RSI for the last a single of trading hit 43.42, and the three-weeks RSI is set at 43.58 for CNS Pharmaceuticals Inc. [CNSP]. The present Moving Average for the last 50 days of trading for this stock 0.3110, while it was recorded at 0.2761 for the last single week of trading, and 0.7455 for the last 200 days.

Insight into CNS Pharmaceuticals Inc. Fundamentals:

Return on Equity for this stock declined to -136.48, with Return on Assets sitting at -114.07.

CNS Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.80 and a Current Ratio set at 13.80.

CNS Pharmaceuticals Inc. [CNSP] Insider Position Details

There are presently around $0 million, or 4.30% of CNSP stock, in the hands of institutional investors. The top three institutional holders of CNSP stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 506,532, which is approximately 242.947% of the company’s market cap and around 2.90% of the total institutional ownership; VANGUARD GROUP INC, holding 427,703 shares of the stock with an approximate value of $0.12 million in CNSP stocks shares; and BANK OF NEW YORK MELLON CORP, currently with $66000.0 in CNSP stock with ownership of nearly 689.341% of the company’s market capitalization.

Positions in CNS Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 11 institutional holders increased their position in CNS Pharmaceuticals Inc. [NASDAQ:CNSP] by around 793,612 shares. Additionally, 12 investors decreased positions by around 234,076 shares, while 5 investors held positions by with 705,952 shares. The mentioned changes placed institutional holdings at 1,733,640 shares, according to the latest SEC report filing. CNSP stock had 5 new institutional investments in for a total of 191,392 shares, while 8 institutional investors sold positions of 23,951 shares during the same period.